

# ForPatients

by Roche

Follicular Lymphoma Chronic Lymphocytic Leukemia

## Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03374137 ML30074

---

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

### *Trial Summary:*

This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

**Hoffmann-La Roche**  
Sponsor

**N/A**  
Phase

---

**NCT03374137 ML30074**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---